- CA$18.00m
- CA$13.70m
- $26.61m
Annual balance sheet for Innocan Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 11 | 4.95 | 3.88 | 5.01 | 6.69 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.169 | 0.243 | 0.694 | 0.536 | 0.944 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 12.5 | 6.88 | 6.8 | 9.15 | 10.4 |
| Net Property, Plant And Equipment | 0.054 | 0.098 | 0.136 | 0.113 | 0.086 |
| Total Assets | 12.6 | 6.98 | 6.94 | 9.26 | 10.5 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.56 | 0.731 | 2.54 | 2.24 | 1.35 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 3.52 | 0.582 | 2.84 | 4.09 | 4.92 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 9.05 | 6.39 | 4.1 | 5.17 | 5.6 |
| Total Liabilities & Shareholders' Equity | 12.6 | 6.98 | 6.94 | 9.26 | 10.5 |
| Total Common Shares Outstanding |